Kissei

Rigel has agreements with Kissei to develop and commercialize TAVALISSE (fostamatinib disodium hexahydrate) and REZLIDHIA (olutasidenib) in Japan and other specified Asian countries.

TAVALISSE

  • Rigel has an exclusive license and supply agreement with Kissei to develop and commercialize TAVALISSE in all potential indications in Japan, China, Taiwan and the Republic of Korea.
  • TAVALISSE launched in Japan in April 2023 for the treatment of adult persistent and chronic immune thrombocytopenia (ITP) and in South Korea in July 2025 for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to a previous treatment.
  • Rigel received an upfront cash payment, is eligible for regulatory and commercial milestone payments, and receives product transfer price payments based on tiered net sales of TAVALISSE in the territory.

REZLIDHIA

  • Rigel has an exclusive license and supply agreement with Kissei to develop and commercialize REZLIDHIA in all current and potential indications in Japan, Taiwan and the Republic of Korea.
  • In May 2026, Kissei submitted a new drug application for marketing approval of olutasidenib in Japan for the treatment of relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation.
  • Rigel received an upfront cash payment, and is eligible for development, regulatory and commercial milestone payments, and product transfer price payments based on tiered net sales of REZLIDHIA in the territory.